Boehringer Ingelheim
Boehringer Ingelheim is a global enterprise that focuses on improving patient health through innovative solutions. Its investment arm, established in 2010, specializes in venture capital for early-stage companies in the life sciences, biotechnology, and digital health sectors. The firm prioritizes investments in groundbreaking therapeutics and novel technologies, targeting areas such as immuno-oncology, regenerative medicine, and infectious diseases. By investing up to €15 million in promising startups, Boehringer Ingelheim aims to foster long-term relationships with scientists and entrepreneurs, facilitating the development of new biological entities, next-generation vaccines, and personalized medicine approaches. With offices in Germany, the United States, and China, the firm primarily seeks opportunities in North America and Europe/Israel, striving to address significant medical needs through pioneering scientific advancements.
Operator of a biotechnology company intended to develop innovative therapies against cancer and other life-threatening diseases. The company uses molecular glue degraders that eliminate the disease-causing protein instead of inhibiting a harmful protein's function by reprogramming the natural protein recycling machinery present in every cell, enabling physicians to change the way incurable diseases are treated.
ViraTherapeutics GmbH, founded in 2013 and located in Innsbruck, Austria, specializes in the development of anti-cancer therapeutics utilizing oncolytic viruses. The company's primary product, VSV-GP, is an innovative oncolytic virus designed to effectively target and destroy cancer cells while sparing normal tissues from damage. ViraTherapeutics is currently engaged in preclinical studies to evaluate the safety and efficacy of VSV-GP, with plans to initiate clinical trials involving cancer patients in the future. In addition to VSV-GP, the company is also focused on developing oncolytic cancer vaccines based on a chimeric virus derived from the vesicular stomatitis virus, advancing the potential of viral therapies in oncology.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
ViraTherapeutics GmbH, founded in 2013 and located in Innsbruck, Austria, specializes in the development of anti-cancer therapeutics utilizing oncolytic viruses. The company's primary product, VSV-GP, is an innovative oncolytic virus designed to effectively target and destroy cancer cells while sparing normal tissues from damage. ViraTherapeutics is currently engaged in preclinical studies to evaluate the safety and efficacy of VSV-GP, with plans to initiate clinical trials involving cancer patients in the future. In addition to VSV-GP, the company is also focused on developing oncolytic cancer vaccines based on a chimeric virus derived from the vesicular stomatitis virus, advancing the potential of viral therapies in oncology.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.